InvestSMART

Chimeric Therapeutics Limited (ASX: CHM) - Announcements

Current share price for CHM : $0.003 0.002 (40%)+

ASX company news and announcements for Chimeric Therapeutics Limited (CHM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Chimeric Therapeutics Limited (CHM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Chimeric Therapeutics Limited (CHM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Chimeric Therapeutics Limited (CHM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$0 Application for quotation of securities - CHM 20 May 2026 5:09PM $0.130 $0.003 fallen by 97.69%
$0 Notice under section 708A 12 May 2026 5:32PM $0.135 $0.003 fallen by 97.78%
$0 Application for quotation of securities - CHM 12 May 2026 5:25PM $0.135 $0.003 fallen by 97.78%
$0 Application for quotation of securities - CHM 12 May 2026 5:20PM $0.135 $0.003 fallen by 97.78%
$0 Proposed issue of securities - CHM 8 May 2026 5:33PM $0.135 $0.003 fallen by 97.78%
$0 Notification of cessation of securities - CHM 5 May 2026 5:02PM $0.155 $0.003 fallen by 98.06%
$0 Change in substantial holding 5 May 2026 2:07PM $0.155 $0.003 fallen by 98.06%
$0 Notification regarding unquoted securities - CHM 4 May 2026 4:45PM $0.160 $0.003 fallen by 98.13%
$0 Notice under section 708A 4 May 2026 4:25PM $0.160 $0.003 fallen by 98.13%
$0 Application for quotation of securities - CHM 4 May 2026 4:20PM $0.160 $0.003 fallen by 98.13%
$0 Application for quotation of securities - CHM 1 May 2026 5:30PM $0.165 $0.003 fallen by 98.18%
$0 Notification regarding unquoted securities - CHM 30 Apr 2026 11:40AM $0.200 $0.003 fallen by 98.50%
$0 Notification regarding unquoted securities - CHM 30 Apr 2026 11:25AM $0.200 $0.003 fallen by 98.50%
$0 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2026 3:41PM $0.210 $0.003 fallen by 98.57%
$0 Capital Consolidation Complete 29 Apr 2026 9:30AM $0.002 $0.003 risen by 50%
$0 Update - Consolidation/Split - CHM 29 Apr 2026 9:23AM $0.002 $0.003 risen by 50%
$0 CHM CORE-NK Phase 1B clinical trial achieves 60% CR/CRi 27 Apr 2026 9:15AM $0.002 $0.003 risen by 50%
$0 Update - Consolidation/Split - CHM 17 Apr 2026 12:34PM $0.001 $0.003 risen by 200%
$0 Results of Meeting 17 Apr 2026 12:22PM $0.001 $0.003 risen by 200%
$0 Notification of cessation of securities - CHM 9 Apr 2026 4:28PM $0.002 $0.003 risen by 50%
$0 Investor presentation 25 Mar 2026 10:07AM $0.002 $0.003 risen by 50%
$0 Chimeric to present at NWR Virtual Healthcare Conference 23 Mar 2026 12:08PM $0.002 $0.003 risen by 50%
$0 Prospectus 23 Mar 2026 8:25AM $0.002 $0.003 risen by 50%
$0 Update - Proposed issue of securities - CHM 19 Mar 2026 8:34AM $0.002 $0.003 risen by 50%
$0 Consolidation/Split - CHM 19 Mar 2026 8:26AM $0.002 $0.003 risen by 50%

26 - 50 of 648 results

Page 2 of 26

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.